| 1 |
35115300 | Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. | 2022 Apr |
1 |
| 2 |
35583123 | Methysticin Acts as a Mechanism-Based Inactivator of Cytochrome P450 2C9. | 2022 Jun 20 |
1 |
| 3 |
34272716 | Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT). | 2021 |
9 |
| 4 |
31854189 | Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4'- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice. | 2020 Feb 17 |
1 |
| 5 |
32272615 | Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. | 2020 Apr 7 |
1 |
| 6 |
32290339 | Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes. | 2020 Apr 10 |
1 |
| 7 |
32406758 | Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. | 2020 May |
1 |
| 8 |
30336288 | Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). | 2019 Jan |
1 |
| 9 |
30690186 | Atipamezole is a promising non-discriminative inhibitor against pan-CYP450 including diclofenac 4'-hydroxylation: A comparison with ABT for drug ADME optimization and mechanism study. | 2019 Mar 15 |
1 |
| 10 |
31318064 | Effect of IS01957, a para-coumaric acid derivative on pharmacokinetic modulation of diclofenac through oral route for augmented efficacy. | 2019 Nov |
1 |
| 11 |
29168292 | Evaluation of the effect of quercetin treatment on CYP2C9 enzyme activity of diclofenac in healthy human volunteers. | 2018 Feb |
1 |
| 12 |
29368187 | Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. | 2018 May |
1 |
| 13 |
29621561 | Different inhibitory effects of azole-containing drugs and pesticides on CYP2C9 polymorphic forms: An in vitro study. | 2018 Aug |
1 |
| 14 |
29710546 | Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin. | 2018 Jun |
1 |
| 15 |
28484907 | Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes. | 2017 Jun |
1 |
| 16 |
26750984 | Investigation of selective inhibitory effects of glycyrol on human CYP 1A1 and 2C9. | 2016 Oct |
2 |
| 17 |
26877175 | On-line coupling of immobilized cytochrome P450 microreactor and capillary electrophoresis: A promising tool for drug development. | 2016 Mar 11 |
1 |
| 18 |
27092633 | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. | 2016 Mar |
2 |
| 19 |
27128896 | Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. | 2016 Apr 27 |
1 |
| 20 |
27287328 | Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro. | 2016 |
1 |
| 21 |
27302079 | Molecular dynamics investigations of regioselectivity of anionic/aromatic substrates by a family of enzymes: a case study of diclofenac binding in CYP2C isoforms. | 2016 Jun 29 |
1 |
| 22 |
27839691 | Modeling of aceclofenac metabolism to major metabolites in healthy volunteers. | 2016 Dec |
2 |
| 23 |
24517573 | Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. | 2015 Apr |
1 |
| 24 |
25994031 | Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. | 2015 Aug |
1 |
| 25 |
26255664 | Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. | 2015 |
1 |
| 26 |
24322786 | High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. | 2014 Aug |
6 |
| 27 |
24550229 | 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. | 2014 May |
1 |
| 28 |
24590863 | Effect of crude extract of Eugenia jambolana Lam. on human cytochrome P450 enzymes. | 2014 Nov |
3 |
| 29 |
24695277 | Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. | 2014 |
1 |
| 30 |
25075423 | Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient. | 2014 |
1 |
| 31 |
25951663 | The role of CYP2C9 genetic polymorphisms in the oxidative metabolism of diclofenac in vitro. | 2014 Dec |
2 |
| 32 |
23153057 | Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy. | 2013 Apr |
1 |
| 33 |
23241944 | Human pharmacogenetic analysis in chimeric mice with 'humanized livers'. | 2013 Feb |
1 |
| 34 |
23641937 | Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9. | 2013 May 29 |
2 |
| 35 |
22311023 | Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.). | 2012 Jun |
1 |
| 36 |
22360448 | Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. | 2012 Aug |
1 |
| 37 |
22447115 | Increased expression of drug-metabolizing enzymes in human hepatocarcinoma FLC-4 cells cultured on micro-space cell culture plates. | 2012 |
2 |
| 38 |
22547083 | Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. | 2012 Aug |
3 |
| 39 |
22943175 | In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates. | 2012 Oct |
1 |
| 40 |
23353843 | The influence of rosuvastatin on liver microsomal CYP2C6 in hereditary hypertriglyceridemic rat. | 2012 |
1 |
| 41 |
20927605 | Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. | 2011 Apr |
1 |
| 42 |
21182487 | Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. | 2011 |
1 |
| 43 |
21220010 | Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. | 2011 May |
2 |
| 44 |
21447389 | Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. | 2011 Jun 14 |
1 |
| 45 |
24250426 | Involvement of Lysosomal Labilisation and Lysosomal/mitochondrial Cross-Talk in Diclofenac Induced Hepatotoxicity. | 2011 Fall |
2 |
| 46 |
19347265 | Predicting drug interaction of clopidogrel on microbial metabolism of diclofenac. | 2010 Mar |
2 |
| 47 |
19960413 | Inhibitory effects of deoxypodophyllotoxin from Anthriscus sylvestris on human CYP2C9 and CYP3A4. | 2010 May |
1 |
| 48 |
20848598 | Study of atypical kinetic behaviour of cytochrome P450 2C9 isoform with diclofenac at low substrate concentrations by sweeping-MEKC combination. | 2010 Oct |
2 |
| 49 |
20877134 | Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. | 2010 |
2 |
| 50 |
19022234 | Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. | 2009 Apr 15 |
1 |